Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study (ACTRN12619001199101)
FRAIL-M
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Andrew Spencer
Teletrial
This trial is being conducted as a teletrial.
A teletrial is where hospitals - regional, rural or city - share a clinical trial and work together to deliver it to their patients all at the same time. This means, for example, you may be on the same trial at your local hospital at the same time as someone 200km away at their local hospital. The entire medical team involved in the one trial use digital communication, such as video conferencing, to closely communicate with each other as one big team. This means you may now have more opportunities to go on a clinical trial at your nearest hospital. Find out more about teletrials at our TrialHub.
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR